机译:FDA批准摘要:Ivosidenib用于复发或难治性急性髓性白血病,具有异柠檬酸脱氢酶-1突变
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Oncol Ctr Excellence Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Oncol Ctr Excellence Silver Spring MD USA;
机译:FDA批准摘要:Ivosidenib用于复发或难治性急性髓性白血病,具有异柠檬酸脱氢酶-1突变
机译:FDA批准摘要:Mylotarg用于治疗复发或难治性CD33a ??阳性急性髓细胞性白血病的患者
机译:FDA批准摘要:Mylotarg用于治疗复发或难治性CD33阳性急性髓性白血病的患者
机译:计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
机译:复发性急性淋巴细胞白血病中NT5C2突变的机制和治疗靶点
机译:FDA批准摘要:Mylotarg用于治疗复发或难治性CD33阳性急性髓细胞性白血病的患者
机译:FDA批准摘要:Mylotarg用于治疗复发或难治性CD33阳性急性髓性白血病的患者